|Specificity:||The mouse monoclonal antibody Ber-ACT35 (also known as ACT35) recognizes CD134 (TNFRSF4, OX40), an approximately 50 kDa type I transmembrane glycoprotein expressed on activated T cells.
HLDA VI: WS Code C-31
|Immunogen:||HTLV 1-transformed HUT-102 cells|
|Species Reactivity:||Human, Non-Human Primates|
|Preparation:||The purified antibody is conjugated with Fluorescein isothiocyanate (FITC) under optimum conditions. The reagent is free of unconjugated FITC and adjusted for direct use. No reconstitution is necessary.|
|Storage Buffer:||The reagent is provided in stabilizing phosphate buffered saline (PBS) solution containing 15mM sodium azide.|
|Storage / Stability:||Store in the dark at 2-8°C. Do not freeze. Avoid prolonged exposure to light. Do not use after expiration date stamped on vial label.|
|Usage:||The reagent is designed for Flow Cytometry analysis of human blood cells using 4 μl reagent / 100 μl of whole blood or 106 cells in a suspension.
The content of a vial (0.4 ml) is sufficient for 100 tests.
|Expiration:||See vial label|
|Lot Number:||See vial label|
|Background:||CD134 (TNFRSF4, also known as OX40) is a type I transmembrane glycoprotein of TNF/NGF receptor family expressed on activated T cells, fibroblasts, and hematopoietic precursors. Binding to its ligand (OX40L, TNFSF4) on antigen presenting cells gives to the T cell costimulatory signal, and this interaction results also in B cell proliferation and influences T cell memory pool. CD134 is upregulated at sites of inflammation, especially in case of multiple sclerosis and psoriatic lesions.|
*Tanijiri T, Shimizu T, Uehira K, Yokoi T, Amuro H, Sugimoto H, Torii Y, Tajima K, Ito T, Amakawa R, Fukuhara S: Hodgkin's reed-sternberg cell line (KM-H2) promotes a bidirectional differentiation of CD4+CD25+Foxp3+ T cells and CD4+ cytotoxic T lymphocytes from CD4+ naive T cells. J Leukoc Biol. 2007 Sep;82(3):576-84.
*Willett BJ, McMonagle EL, Ridha S, Hosie MJ: Differential utilization of CD134 as a functional receptor by diverse strains of feline immunodeficiency virus. J Virol. 2006 Apr;80(7):3386-94.
*Li M, Zhang Y: The effect of anti-human CD134 monoclonal antibody on phytohemagglutinin-induced mRNA expression of perforin in peripheral blood mononuclear cells. Cell Mol Immunol. 2005 Dec;2(6):467-71.
*Voo KS, Bover L, Harline ML, Vien LT, Facchinetti V, Arima K, Kwak LW, Liu YJ: Antibodies targeting human OX40 expand effector T cells and block inducible and natural regulatory T cell function. J Immunol. 2013 Oct 1;191(7):3641-50.
*Endl J, Rosinger S, Schwarz B, Friedrich SO, Rothe G, Karges W, Schlosser M, Eiermann T, Schendel DJ, Boehm BO: Coexpression of CD25 and OX40 (CD134) receptors delineates autoreactive T-cells in type 1 diabetes. Diabetes. 2006 Jan;55(1):50-60.
*Aten J, Roos A, Claessen N, Schilder-Tol EJ, Ten Berge IJ, Weening JJ: Strong and selective glomerular localization of CD134 ligand and TNF receptor-1 in proliferative lupus nephritis. J Am Soc Nephrol. 2000 Aug;11(8):1426-38.
*Jones D, Fletcher CD, Pulford K, Shahsafaei A, Dorfman DM: The T-cell activation markers CD30 and OX40/CD134 are expressed in nonoverlapping subsets of peripheral T-cell lymphoma. Blood. 1999 May 15;93(10):3487-93.
For laboratory research only, not for drug, diagnostic or other use.
EXBIO Praha | Nad Safinou II 341 | 252 50 Vestec u Prahy | Czech Republic